Martina Fiumara

Milan, 20132, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 12 publications

Decoding VEXAS syndrome: emerging insights into pathogenesis and clinical management.

Decoding VEXAS syndrome: emerging insights into pathogenesis and clinical management.

Journal: Current opinion in rheumatology

Published: November 01, 2025

Nanoengineered 3D culture substrate enables superior persistence and polyclonal engraftment of genetically engineered hematopoietic stem cells.

Nanoengineered 3D culture substrate enables superior persistence and polyclonal engraftment of genetically engineered hematopoietic stem cells.

Journal: Cell stem cell

Published: June 18, 2025

Clonal hematopoiesis meets an autoinflammatory disease: the new paradigm of VEXAS syndrome.

Clonal hematopoiesis meets an autoinflammatory disease: the new paradigm of VEXAS syndrome.

Journal: Expert review of hematology

Published: May 21, 2025

TIGIT disruption rescues the antitumor activity of low avidity TCR-engineered T cells by increasing TCR signal strength.

TIGIT disruption rescues the antitumor activity of low avidity TCR-engineered T cells by increasing TCR signal strength.

Journal: Nature communications

Published: April 15, 2025

Selection of human hematopoietic stem cells bearing the intended functional edit by transient AND-gate reporters.

Selection of human hematopoietic stem cells bearing the intended functional edit by transient AND-gate reporters.

Journal: Nature biotechnology

Published: October 29, 2024

Mechanisms of hematopoietic clonal dominance in VEXAS syndrome.

Mechanisms of hematopoietic clonal dominance in VEXAS syndrome.

Journal: Nature medicine

Published: July 08, 2024

Metformin reduces the clonal fitness of Dnmt3a R878H hematopoietic stem and progenitor cells by reversing their aberrant metabolic and epigenetic state.

Metformin reduces the clonal fitness of Dnmt3a R878H hematopoietic stem and progenitor cells by reversing their aberrant metabolic and epigenetic state.

Journal: Research square

Published: February 26, 2024

Author Correction: Genotoxic effects of base and prime editing in human hematopoietic stem cells.

Author Correction: Genotoxic effects of base and prime editing in human hematopoietic stem cells.

Journal: Nature biotechnology

Published: January 25, 2024

Metformin reduces the competitive advantage of Dnmt3aR878H HSPCs.

Metformin reduces the competitive advantage of Dnmt3aR878H HSPCs.

Journal: Nature

Published: January 18, 2024

Unbiased assessment of genome integrity and purging of adverse outcomes at the target locus upon editing of CD4+ T-cells for the treatment of Hyper IgM1.

Unbiased assessment of genome integrity and purging of adverse outcomes at the target locus upon editing of CD4+ T-cells for the treatment of Hyper IgM1.

Journal: The EMBO journal

Published: April 04, 2023

Genotoxic effects of base and prime editing in human hematopoietic stem cells.

Genotoxic effects of base and prime editing in human hematopoietic stem cells.

Journal: Nature biotechnology

Published: November 21, 2022

Mobilization-based chemotherapy-free engraftment of gene-edited human hematopoietic stem cells.

Mobilization-based chemotherapy-free engraftment of gene-edited human hematopoietic stem cells.

Journal: Cell

Published: December 16, 2021

Showing 1-12 of 12

Last Updated: 09/26/2026